The Medical Advisor

OneDayMD Master Evidence Guide • Updated September 2026 Semaglutide, tirzepatide, oral GLP-1 medicines, retatrutide and the next generation of metabolic therapies have changed the obesity and cardiometabolic treatment landscape. But the phrase “GLP-1 drug” can hide major differences in mechanism, indication, dose, study population and clinical evidence. This master guide organizes the most important clinical trials into an ebook-style reference—from the landmark STEP and SURMOUNT obesity trials to SELECT , FLOW , SUMMIT , ESSENCE , OASIS 4 , ATTAIN-1 , TRIUMPH, SURPASS  and the emerging CagriSema program. 2026 update: The field has moved beyond injections alone. Oral semaglutide (Wegovy tablets) and orforglipron (Foundayo) are now U.S. FDA-approved options for weight management, while higher-dose semaglutide (Wegovy HD) has also ...

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: August 19, 2026 Peptides are short chains of amino acids (typically 2–50 residues) that function as high-specificity signaling molecules across endocrine, neurologic, immune, metabolic, and regenerative systems. In clinical practice they range from decades-old, life-saving hormones like insulin to blockbuster metabolic drugs like semaglutide — and, increasingly, to a class of unapproved "research" peptides whose regulatory status changed twice in 2026 alone. This guide synthesizes the mechanistic biology, evidence grading, approved indications, safety considerations, and — new for this update — a full breakdown of the FDA's July 2026 advisory-committee vote on compounded peptide access, decoded for both clinicians and patients. Quick Answer (AI & Search Summary) Peptides already underpin FDA-approved drugs like insulin and the GLP-1 agonists. A separate group of inves...